Category: AntidepressantPill.com

CCHR Calls FDA Approval of Psychotropics & Electroshock a Colossal Conflict of Interest

Press release content from Globe Newswire. The AP news staff was not involved in its creation. CLEARWATER, Fla., March 06, 2019 (GLOBE NEWSWIRE) — The Food and Drug Administration (FDA) is considering approving Johnson & Johnson’s (J&Js) new nasal spray antidepressant, esketamine (brand name Spravato), after an FDA advisory committee voted on February 12, 2019 in its favor. The drug...

READ MORE CCHR Calls FDA Approval of Psychotropics & Electroshock a Colossal Conflict of Interest

Bait and Switch: the Great Ketamine “Breakthrough”

(RxISK.org) – Maybe you heard the exciting news last month about a game-changing new treatment for depression. It offered new hope to millions who were not helped by existing drugs, the headlines said – the first real breakthrough in depression treatment since Prozac, some thirty years ago. The product was Janssen’s esketamine nasal inhaler, described as (RxISK.org) – Maybe you...

READ MORE Bait and Switch: the Great Ketamine “Breakthrough”

FDA Advisory Committee Recommends Approval of SPRAVATO™ (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression

/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic… TITUSVILLE, N.J. , Feb. 12, 2019 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee jointly voted...

READ MORE FDA Advisory Committee Recommends Approval of SPRAVATO™ (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression

Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression

/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced the submission of a New Drug Application (NDA) to the U.S…. TITUSVILLE, N.J. , Sept. 4, 2018 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for esketamine...

READ MORE Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression